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PSYCHOTROPI C DR UGS IN PR EG NA NCY
Pregn an cy is fr eque nt ly complicated by th e development or recurrence of a
serious mental di sorder ; neurotic, major affec t ive , an d psychotic illnesses have
all been obse rved (1-4) . Wh en a major mental di sorder arises in a pregnant
woman and threaten s th e health or life of th e patient and/or fet us , it should be
treated ea rly and aggressively to m in im ize co mplica tions and foresta ll the
advance of th e d isease. Nonbiologic methods like individual psychotherapy,
co up les or fami ly th erapy, social casewor k, and hospi ta lizat ion in a suppo rtive,
struc ture d mili eu should form th e first line of treatment. Electroconvu lsive
th erapy (ECT) may be th e treatm ent of choice fo r so me pati ent s, e .g. , a first
trimester mother with a life-threat ening episode of bipolar illness. If th e illness
persists in spite of nonbiological interventions, and if th e r isks of the inad e-
quately treated disease ou twe igh th e ri sks associa ted with a po tent ially usefu l
medication , th en a trial of th at medicati on is clearly ind icated .
However , the ph ysician 's d ilemma occurs because although as many as 80
percent of pregnant women tak e prescribed drugs, and up to 35 percent take a
psych oacti ve drug (5 ,6), no psych otropic d rug has been proven safe for use
during pregnancy, and all car ry warnings by th e FD A (7) . Furthermore , in
ca lculating th e medication's risks, th e physician mu st rel y mostly on an imal data
and suboptimal human epidemiologic stud ies . In th is review I will first o utl ine
the types of risk posed to mother and fetus by dr ugs in genera l, with special
attention to th e fea tures of mat ernal and fetal physiology wh ich increase th ose
ris ks. I will th en consider th e r isks and benefits associa ted with antipsych otics,
antidepress ants, and lithium, suggest ing guidelines for th eir use in the pregnan t
pati ent.
Maternal physiology and risk. For those patients requiring drug treatment ,
the ri sks to th e mother are similar to th e risks posed to the no n-pregnant patient ,
but are co mpo u nded by th e metaboli c, endocr ine, renal , and ca rd iac changes in
pregn an cy. Delayed gastric emptying and increased in testinal transit t ime may
lead to slower but more co mplete drug abso rp t ion. Plasma vo lume, total body
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water, and body fat are increased, resulting in a higher volume of distribution
and a lower serum concentration for any given dose of drug. T h is increases th e
volume of fluid which the kidney must in some cases clear of drug (8) . This may
or may not be counterbalanced by the steady increase in renal blood flow and
glomerular filtration rate which tend to speed th e clearan ce of free drug.
Although albumin production is normal or increased, pla sma albu min concen-
tration falls and total plasma drug concentration is decreased. If the total
circulating albumin is reduced, as by pre-eclampsia or th e neph rotic syndrome ,
binding sites can become saturated and free drug fracti on r ises (9). The
hormonal milieu of pregnancy is thought to increase metab ol ic ac tivity in th e
liver (8) and may tend to speed breakdown of some drugs.
Fetal physiology and risk. Further complicating the use of drugs in pregnancy
is the presence of an additional but equally complex patient, the fetus. All
psychotropic drug classes cross the placenta. Transfer occurs primari ly by
simple diffusion , dependent upon the chemica l properties of th e drug (including
molecular size, protein-binding affinity, polarity , and lipid so lub ility), drug
concentration, and duration of exposure (10) . Non-ionized, low molecu lar
weight, lipid-soluble drugs are well absorbed. Placental metabolism of d rugs is
probably less active than metabolism within the fetal liver. Intend ed or
unintended drug effects may act to reduce placental blood flow or interfere with
active transport and other nutritive functions of the placenta.
Compared to the adult, fetal cardiac output is greater and a higher
proportion of blood flow is distributed to the brain. Combined with greater
blood-brain permeability this leads to more rapid and more co mplete drug
exposure of the fetal brain (11) . Total concentration of plasma prote in and
protein-binding affinity are less in the fetus than in th e mother , leaving more
free drug available for tissue penetration and competition with o ther drugs and
endogenous compounds for protein binding (10). Drugs are metaboli zed chiefly
in the fetal liver, where the activity and concentration of ce r tain microsomal
enzymes is less than in the adult, prolonging and exagge ra ting drug effects.
Excretion of most drugs, via the placenta and fetal urine, is delayed.
Like the fetus, the neonate has proportionally less total ser um pro tei n for
binding, less active hepatic degradative enzymes, and lower glomerular filtra-
tion rate than the adult (9). The blood-brain barrier is still incomplete and the
immature central nervous system (CNS) appears generally more se nsi tive to
drug effects (10) . Furthermore, the neonate no longer exists in equilib rium with
its mother via the placenta, and a drug concentrated in th e fe tus shor tly before
birth may have significantly prolonged postnatal effects.
The risks to the fetus include teratogenic effects, long-term neurobehav-
ioral effects, and direct toxic effects. A teratogenic effect may be immediate or
delayed ; it ma y consist of abortion , malformation, altered fetal growth, func-
tional deficit, carcinogenesis, or mutagenesis. Psychotropic drugs ca n also
produce long-term functional effects which are not accompanied by gross
st ructu ral malformations and which may not be measureable or mani fest for
24 JEFFERSON JOU RNAL OF PSYCHI ATR Y
yea rs after bi r th. Since the pioneering studies of Werboff and co lleag ues
estab lished th e field of behavioral teratology (12, 13), numerous subsequent
an imal stu d ies have shown th at p renatal ex posure to a variety of psychoactive
drugs can d isturb nerve ce ll proli feration and d ifferentiat ion (14 ), neuro-
t ra nsmitter concentrations (15), and behavio ral development and performance
(16, 17). Such psyc hoteratogenicity ma y be expressed as disturbed psychomotor
activity, fau lty adaptation to the extra-uterine environment, abnormal learning
or problem-sol ving capacity, or o ther more sub tle cognitive deficits and mood
disturban ces.
In human s, alcohol, opiates, and d iphenyl hydantoin are already well-
es tab lished psych oteratogens, capa b le of p roducing disturbances of arousal and
motor coord ination as well as specific learning disabilities and mental reta rda-
t ion (18-20).
Fu ncti o nal behavioral or psych o logical effects may occur at drug doses
lower than those required to produce structural defect s (2 1), or they ma y arise
when exposure occu rs afte r th e period of organogenesis but during the latter
hal f of pregnancy or early postn at al life when CNS development and maturation
is st ill ongoing . Effec ts may even be so su bt le as to be manifest only if th e
post-natal environment is enriched or impoverished (22) making routine detec-
tion di fficul t. Eve n drugs whi ch induce only transient early behavioral cha nges
may lead to permanent behavioral consequences through disturbance of early
env ironmenta l, including mother- infant, in teractions. Neonatal depression (23),
hyperacti vity, and irritability, as well as mood or behavior disturbances may all
interfe re with the ea rly moth er-infant relationship .
Relatively little atten tio n has been given to studying the long-term neurobe-
havioral an d psych ological effects in humans of pre-natal exposure to the
antipsyc hotics, antidepressants, and lithium. T he few follow-up stu d ies available
will be d iscussed under the d rug classes to whic h they apply, but th e clinician
should be awa re that our kn owledge in this area is inadequate and the
implica tio ns for ex posed offspri ng are potentiall y grave. Not only is caution in
prescribing adv ised, but long-term , syste matic fo llow-up of the ch ild ren is
cruc ial.
Direct tox ic effects on the fetus an d neonate include the potentiall y
reversib le, dose-re lated effects which may be exaggerated by the immature fetal
and neonatal metabolism . Drugs ad ministered at or near term may concentrate
in th e fetus, and afte r deli very, when clearance depends upon immature
neonatal mech anisms, drug effects may be prolonged . Chronic prenatal admin-
ist ra tion ma y lead to feta l dependence and ultimately neonatal withdrawal
symptoms when drug ex posure ceases at b irth .
Methodological difficulties. The ca lculation of a specific risk and summa tion of
a to ta l r isk to th e pat ien t and her fetus is a difficult, if not impossible , ta sk. For
ethical reasons, randomized p rospect ive clinical trials of psychotropic drug
effects on pregnant women have not and should not be performed. Animal
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studies can be carefully controlled and may suggest a potential r isk, bu t species
differences can be profound and extrapolation from animal stud ies is always
tentative.
To date, all human studies on the effects of psychotropic drugs in
pregnancy suffer from poor control of potentially confounding var iables suc h as
maternal age, gravidity, and parity, as well as history of miscarriages, still births,
and prior malformed infants. Maternal nutrition , alcohol use , cigarette use , an d
over-the-counter and prescription drug use all need to be carefully controlled or
at least matched. The dose of drug, duration of exposure , and timing of
exposure are critical variables, exemplified by thalidomide's ab ility to produce
limb defects only between the 42nd and 48th days of gestation (24). Thus a study
which combines all first trimester drug exposures ma y miss a sub tle effect
produced only during a brief gestational " window." The mother's illn ess and
the indication for drug use is another often neglected variabl e. Many of the
studies on phenothiazine effects were carried out on patients with nausea and
vomiting rather than a mental disorder. These doses were lower, and duration
of treatment shorter, than those relevant to treatment at mental illness. Fina lly,
the length and thoroughness of follow-up is generally inadequate . As Ed lund
and Craig (25) have shown, the cumulative incidence of congenital anomalies
increases with increasing length of follow-up. Therefore, if we hope to detect
subtle or delayed neurobehavioral effects in children exposed prenatall y to
psychotropic drugs, our observations must be both ext ensive , in te rms of
neurobehavioral assessment techniques, and extended, ideally into ad u lthood .
ANTIPSYCHOTIC DRUGS
Indications. The antipsychotic drugs have repeatedly been shown effec tive
in the treatment of acute psychotic episodes occurring in schizoph ren ic, affec-
tive, and a variety of other mental disorders (26). They have been used
effectively to treat psychotic symptoms in pregnant women as well.
Adverse Effects on Mother. Sedation, postural hypotension , antich ol inergic
and extrapyramidal symptoms may occur. Anticholinergic effec ts on th e bowel
ma y worsen the constipation which is common in pregnancy. Lik ewise the
sedative effect ma y compound the pregnant woman 's fatigue . Most impor tant ,
however, is the potential effect on maternal blood pressure , and th e potent ial
compromise of placental blood flow should always be kept in mind. The risk of
tardive dyskinesia of course always pertains.
Teratogenic Effects. Phenothiazines and thioxanthenes have been shown to
pass the placental barrier (27,28) and phenothiazines have been measu red in
va r ious concentrations in fetal brain and liver.
Most reviews of the use of chlorpromazine, haloperidol , o r perphenazine in
human pregnancy find no statistically significant increase in th e inc iden ce of
major congenital structural malformations in exposed offspring (29 - 36). In a
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prospective survey of 12 ,764 pregnant women , Rumeau-R ouquette and asso-
ciates (37) found a statistically significant increase in the numbe r of infants born
with maj o r malformations when exposed prenatally to phenothiazines with a
three-carbon alip hatic side chain (chlorpromazine, methotrimeprazin e , t r irne-
prazine, and oxomemazine). Compared to non-exposed co n trols, a similar
increase was not observed with promethazine or the pipe razine and piper id ine
antipsychotics . Of the implicated drugs, on ly chlorpromazin e is used as an
antipsychotic in the United States, and although this study might provid e reason
for avoiding ch lorpromazine, many confounding factors among those women
were not considered. Probably the best controlled study to date is the one by
Milkovich and van den Berg (38). Among 20,504 pregnant women fo llowed
prospect ivel y, 19 ,952 were t reated for nausea and vomiting during their first
trimester, mostly with phenothiazines and especiall y prochlorperazine. Mater-
nal age, type of drug, and gestational age at exposu re were co ntrolled . They
found no increase in the rates of severe congenital anomaly and perinatal death
fo r th e exposed group co mpared to controls. However, no doses were recorded
and co mpliance was not assessed. When used as antiemetics, the pheno th iazines
are likel y to be used intermittently and in lower doses than those needed for the
treatment of psychosis .
Long-Term Neuro behavioral Effects. Animal studies have found that prenatal
exposure to antipsychot ic d rugs can affect vascu logenesis (39) , neuro genesis (40 ,
41), central catecholamine le vel s (15), and dopamine receptor function (42).
Some animal studies report persistent abnormalities of learning behavior (16 ,
43,44) wh ile others do not (45).
Data on long-te rm behaviora l consequences in humans is scarce. After
severa l case reports of persistent neurobehavioral abnormali ti es in infants of
mothers treated with phenoth iazines (46), Desmond and associates (4 7) repo rted
o n 19 in fan ts born to mo th ers o n p henothiazines. Agitation and hype rtonicit y
persisted for severa l months after birth. Many of these infants were a lso ex posed
to alcohol and bar b itu ra tes in utero, however, and the e ffect co u ld not be
attributed to a single drug . Stone (36) found no difference in lQ sco res at fo ur
years of age be tween 151 chi ld ren exposed to phenothiazines in utero a nd
controls who were not exposed. Kr is (48) followed 52 children e xposed to low
doses (50- 150 mg/ day) of ch lorpromazine prenatally, and found no behavioral
or intellectua l abnormalities. H o we ver , these represent small samples of chi l-
d ren, generally exposed to low doses of a ntipsychotic medication at variable
ti mes in gestation ; be tte r co ntrolled, more rigorous follow-up studies are
needed .
Direct toxic effects on thefe tus and neonate. Direct toxic effec ts o f an tipsychotic
d rugs which have been observed in newb o rns include motor r estlessn ess,
abnormal movements, hype r to n ia , and tremor (46,49-51). Functi onal bowel
obstruction and neo natal jaundice have also been described (52). In vitro studies
have ra ised the possibil ity of toxic effects on ch romosomes (5 3), lymphocytes
(54), an d the feta l r e tina (55).
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Recommendations. For the woman with a chronic psychotic di sorder or at risk
for an ac u te psychotic episode during pregnancy, early comprehensive obstetri-
ca l and psychi at ric management and social support should be instituted. Crisis
intervention techn iqu es a re useful at the first sign of deterioration. If th e patient
is un stabl e , hospi tali zati on and use of a th erapeut ic m ilieu should be tried first.
If psych otic sympto ms severe enough to th reat en the life or health of th e
woman or her fetus persist in spi te of aggressive nonbiologic treatment, the use
ofan antipsyc hotic d rug is indica ted, but delay is recommended through the first
trimester if at all feas ib le . Obtai n in for med consent from th e patient and her
spouse if possible. In choosing a drug, consider the patient's prior drug response
and to lerance of side effects, o r that of family members if applicable. Use the
side effect profi le of the antipsychotic drug to optimize treatment of the
patient's symptoms . If she is profoundly agitated and sleepless, choose a low
potency d rug like thioridazine or ch lorpromazine, but beware of hypotensive
effec ts. Otherwise , a high potency agent like haloper ido l or fluph enazine is
ge nera lly pre ferred. G ive a low in itial tes t dose and increase caut iously until th e
minimu m effec t ive dose is reach ed .
T he treatment goal is sufficient control of symptoms to ensure th e safety of
the woman an d her fetus to te rm; it is not necessary or ad visab le to str ive for
complete eradication of sym ptoms. Anticholinergic medications ma y be used if
necessary for treatment of extrapyramidal symptoms, but these medications a lso
have potential for toxic effects on the fetus . Avoid the use of other medica-
tions.
T here is co nsiderab le ev idence that maintenance use of antipsych ot ic
medicat ions after remission of the ac ute phase he lps prevent relapse , bu t
mainten an ce drug treatment should be based o n the severity of symptoms, the
chronicity of th e illness, and th e availability of soc ial support systems. Consider
th e natural h istory of the individual patient's illness, and reduce or discontin ue
th e medication if at a ll poss ib le .
ANTIDEPRESSANTS
Indications. Heterocyclic antidepressants are generally the treatment of first
choice for major depression and the depressed phase of bipolar disorder. T hey
have also fo und th e rapeutic usefulness in dysth ym ic d isorders, atypical depres-
sions, personality di sorders with depressed mood, panic and phobic disorde rs,
obsessive-co mpu lsive disorders, chron ic pa in syndromes, and depression in
schizophrenia an d sch izo-affective disorders (26,56). They ma y be indicat ed in
pregnancy when th e mother's depression is severe enough to threaten the life
and hea lth of hersel f and her fe tus . This includes suicidal intent, vegetative and
nutri tional d istu rbance , or severely impai red functioning and judgemen t not
responsive to no nbi ologica l interventions including hospitalization .
Adverse effects on the mother. These include anticholinergic effects (dry
mouth , decreased G I motility, mydriasis, cycloplegia, urinary hesitancy or
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retention, tachycardia, and delirium), orthostatic hypotension and sedation .
Imipramine and other tertiary amines more co mmonly ca use hypotension and
should generally be avoided in favor of less hypotensive drugs.
Teratogenic effects. Imipramine and desipramine ha ve been shown to cross
the placenta in animals and humans (57,58). In at least one animal study
imipramine and desipramine were found to cross the pla centa and to potentiate
the pressor response to norepinephrine, whil e amitriptyline and protriptyline
did not. Van Petten (58) noted that even closely related co mpo unds can show
differences in penetration of the placenta and subsequent pharmacologic
effects on the fetus. Demonstration of such differences in human pregnancies in
the future could facilitate th e choice of the antidepressant safes t for the fetus.
Sporadic case reports suggest ing a possibl e associati on between maternal
imipramine or amitriptyline use and fetal limb reduction deformities have
appeared in th e literature (59,60). One retrospective case co ntrol study of 2,784
cases of birth defects was inconclusive (61), while other sma ll co hort studies
(62-65) found no causal relationship between maternal imipramine or am itrip-
tyline intake and congenital anomalies in th e offspring.
Long-term neurobehavioral effects. Animal stud ies have clearly demonst rated
that prenatal exposure to tricyclic antidepressants, in th erapeutic doses, can
produce behavioral and neurochemical disturbances lasting well past termina-
tion of drug exposure and into adulthood. Rats exposed prenatally to imipra-
mine show decreased hypothalamic dopamine levels and decrea sed cortical beta
adrenergic receptors (66), delayed reflex development and decreased explor-
atory responses (67), and reduced physiological and behavioral responsiveness as
adults (68) . Similar results have been obtained after prenatal clomipramine
exposure (69). Early neonatal treatment of rats with a monoamine ox idase
inhibitor has resulted in nerve cell changes and decreased co ncentrations of
norepinephrine and dopamine in the hypothalamus, reduced learning capacit y,
and diminished emotional reactivity in later life (70-72). Neurobeh avioral
follow-up studies in humans have not been done .
Recommendations. Antidepressants should be rese rved for th e pregnant
woman whose depression is severe enough to threaten th e life and heal th of
herself and her fetus, and which is unresponsive to nonbiologic interventions.
Reactive depressions or biological depressions th at are less severe should be
treated with psychotherapy alone or in a th erapeutic mili eu. A ca reful his tory,
especially of cardiac diseases, review of systems, physical examination and EKG
should precede the initiation of treatment. Inquire about a prior response to a
spe cific antidepressant or to ECT.
In general , avoid the tertiary amines (im ipramine, amitrip tyline) because of
their increased hypotensive effects. A reasonable choice for card iac safety is
trazodone if sedation is desired, desipramine if it is not. These drugs have
relatively low anti-cholinergic effects as well. Begin with a low dose and increase
slowl y, using plasma drug levels and clinical response to ach ieve the minimal
dose effective in relieving the maj or depressive symptoms . Monitor pulse,
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orthostatic blood pressure changes, and EKG if an y abnorma lity is found on th e
baseline EKG. Give the entire daily dose at bedtime if dayt ime sedation is to be
avoided or nighttime sedation desired. Divide or reduce th e dose if the patient
develops hypotension , hypertension , arrhythmias, fainting, or hea r t failure.
Persistent adverse cardiovascular effects ma y necessitate sto pping th e drug.
Avoid co-administration of other drugs, over-the-counte r or prescr iptio n ,
especially those that affect the cardiovascular system. If at all possib le , avoi d the
use of antidepressants during the first trimester, and attempt to reduce or
discontinue the medication before term. There is a particularly high ris k of
depression in the post-partum period, when resumption of medicat ion and
avoidance of breastfeeding may be indicated.
LITHIUM
Indications. Lithium is the drug of choice for prophylaxis against bipolar
affective episodes of the manic type. It also carries FDA approval for use in acute
manic episodes and in prophylaxis against the depressive phase of bipolar
disorder (73). It may also be useful in acute depression for pa tients who are
unresponsive to other somatic treatments, as prophylaxis aga inst recurrence of
schizoaffective illness, in disorders of impulse control and episod ic violence , and
possibly in some alcoholics.
Approximately one-half of patients with bipolar di sorder are women , and
the first manic episode typically occurs before age 30, well with in th e lim its of a
woman's reproductive life . Women may first manifest th e di sorder during a
pregnancy, and may have up to 50 percent risk of developing a post-p artum
psychosis which can appear from da ys to weeks following th e birth (2). Pract i-
tioners in both obstetrics and in general psychiatry will undoubtedly encounter
pregnant patients with bipolar disorder.
Adverse effects on mother. Lithium presents the sam e spectr um of side effects
and adverse reactions for pregnant women as for others (endoc r ine, rena l,
gastro-intestinal, neurologic), but ph ysiological changes in pregnancy may
increase the relative risk. Progressively increasing lithium clearance by the
kidney may require increasing lithium dose to maintain a th erapeutic serum
concentration. The precipitous fall in glomerular filtration rate and lithium
clearance after delivery may leave the patient toxic (74). The use of thiazide
diuretics or sodium restriction to treat hypertension or edema of pregnancy may
change the fluid and electrolyte balance and quickly lead to maternal and fe tal
lithium toxicity (75).
Teratogenic effects. Lithium freely crosses the placenta, and th e concentrati on
in cord blood equals that of maternal serum (76).
Lithium has repeatedly been shown to be teratogenic in premammal ian
species, causing abnormal tissue differentiation, disorganized eNS develop-
ment, and head and neck anomalies (77 ). Studies in non-human mammals are
contradictory; one showing lithium to be teratogenic (78), while others do not
30 JEFFERSON JO URN AL O F PSYCH IATRY
(77). One study showed an adverse effect on human chromosomes in vitro but
lithium levels used were in the toxic range.
In order to assess the possible teratogenic effect of lithium in h umans, the
International Register of Lithium Babies was begun in 1968. Although the
incidence of malformations in babies of untreated mothers with affective
disorders is unknown, and although a study of this design cannot produce a true
incidence of malformations, pathologic trends ma y be revealed (79). Consecu-
tive reports from 1971 to 1975 revealed increasing likel ihood th at lithium
exerts a teratogenic effect in humans, especially on the developing ca rdiovascu-
lar system (80-82). As of 1980, 225 babies exposed to lithium in th e first
trimester of pregnancy had been reported to the register, 25 of whom were born
with congenital malformations. Besides one baby with intracerebral to xo plasmo-
sis, two with Down's syndrome, and seven stillborn; 18 of th e 25 ba bies with
congenital malformations had involvement of the heart and great vessels, six of
them the exceedingly rare Ebstein's anomaly (comprising defect s of th e tr icu s-
pid valve, atrial septum, and right ventricle). Lithium is therefore gen erally felt
likely to be teratogenic with respect to the cardiovascular system when adminis-
tered in the first trimester (83 ,84).
Long-term neurobehavioral effects. A stu dy of behavioral effects on rats
exposed to lithium in utero showed a significant decrease in performan ce o n a
T-maze and changes in avoidance behavior (85), but animal stud ies may not
reflect the effects on humans. A case report exists of developmental moto r de lay
persisting at one year of age in a human infant found to be lith ium to xic at birth,
but it is not clear whether the motor delay was due to high lithium levels at b irth
or due to cerebral hypoxia associated with lithium-induced cardiac hypofunction
(86). A follow-up study of 60 lithium children not malformed at birth did not
reveal any significantly increased frequency of ph ysical or mental ano malies in
the lithium children as compared to sibling controls (87 ), but co nclusions were
based only on mothers' subjective assessments, not ac tua l exa mi nation or
neurobehavioral testing.
Direct toxic effects on the fetus and neonate. Several authors have reported
neonatal toxicity in the offspring of mothers on toxic or even th erapeutic doses
of lithium at the time of delivery (75,88,89). Findings in th e neonat e incl ude:
cyanosis, muscle flaccidity and hypotonia, poor suck and grasp reflexes, absent
Moro reflex, and lethargy which may take up to 10 days to resol ve. Other
adverse effects reported in the neonate include atrial flutter (90) , func tio na l
tricuspid regurgitation and congestive heart failure (91) , reversibl e in hibition of
fetal th yroid (92), and nephrogenic diabetes insipidus whi ch persisted for two
months after birth (93).
Recommendations. Lithium should be used in pregnant wom en on ly for
unequivocal indications, and on ly after careful consideration of all potent ial
risks and benefits. Women with a history of bipolar disorder have a high ri sk of
developing a manic episode off lithium, as studies have shown th at 70 percent of
patients will have at least one relapse within a year of discontinuing lithium
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versus 20 percent of th ose who are mainta ined o n lith ium . A pregnant woman in
an ac ute manic phase ca n do se r ious harm to he rsel f and her fetus. On the o ther
hand , use of lithium carries multiple potential se r ious ris ks to both mother and
ch ild as outlined above.
Women on lithium should be urged to avoid pregnancy and to mainta in
effect ive co ntraceptio n . One wh o plan s to become pregnant or wh o inad ver-
tently becomes pregnant shou ld be withd rawn fro m lithium prophylaxis during
the first trimester unless there is convi nc ing evi dence that doing so wou ld
enda nger the woma n or he r fetus. T he decision to institute , continue , or
discontinue lithium ad minis trat ion in a woman for whom pregna ncy is a fact o r a
possibility shou ld be made with the co llaboratio n and informed participati on of
both the pati ent a nd her mate .
If a pregnant woman develops an ac ute manic episode, hospitalization wit h a
st r uc tured, supportive mili eu a nd regular individual psyc hotherapy would be
ind ica te d first. Judging by cur rent ly available e vidence, antipsyc hotic drugs are
probabl y safer th an lithium in the fir st trimester, and more rapid ly effective for
ac ute manic symptoms. Choose a low-dose, high -po tency agent at th e lowest
dose e ffec tive in all eviating dangerous symptoms.
If it is believed safest fo r the woman a nd he r fetus to institute lithium
treatment aft er th e first third or half of pregnancy, use the minimum dose
necessa ry to ach ie ve the desired th erapeutic or p rophylact ic e ffec t , achievin g a
serum le vel of 0 .7 to 1.2 m Eq/L in most cases. A single lith ium dose shou ld no t
exceed 300 mg, g iven as often as necessary to ac hieve the target serum
concentration . T his avoids " pu lses" of lith ium wh ich may be more harm ful to
the fe tus th an a steady se rum co ncentra tion . Se rum lith iu m levels should be
closely monitored, as ofte n as weekly towards th e end of pregnancy and even
more frequently in the days before term. Mon ito r thyroid sta tus duri ng
pregna ncy an d use th yr oid supplement as needed to protect mother and fe tus
agains t goite r fo r mat ion . So di um-deplet ing diure tics should not be used :
sod iu m-rest r icte d d iets shou ld be used on ly with great ca ution . Red uce th e da ily
lithium dose by 50 percent in the last week of gesta t ion and stop complete ly at
th e o nse t ofl abor. Reinstitute lithium at pre-pregnan cy dosage (or 50 percent of
the te rm dosage if no pre-pregn ancy dose was es tab lished) as soon after delivery
as fluid homeostasis is re-established, usually three days.
In co nclusion , it is not infrequent that a pregnant woman will develop
psychotic or affective symptoms severe e nough to threaten th e life or health of
herself and her fe tus. Early a nd ag gressive nonbiologic therapies, includi ng
hospitalization and suppor tive mili eu treatment, shou ld be ins titu ted firs t. If the
patient 's symptoms persist, the use of an ant ipsychotic, a n tidepressant , or
antimanic medication should be co ns idered . The decision rests upon a calcu-
lation and balanc ing of the ri sks associa te d with the untreated illness , and the
ri sks assoc iate d with the drug. T h is paper has attem pted to review th e dat a
ava ilab le on the risks of th ese drugs to th e pregnant woman and he r fetus, for it
is this data upon whi ch cur rent clinical decisions must be made. I have also
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attempted to stress the limitations involved in most of th e stu d ies to dat e , and
to suggest the development of more carefully controlled, more extensively
followed-up studies in the future .
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